Studies what drives prostate cancer growth and spread over time
Looks at factors that affect how prostate cancer progresses in adults with standard care.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Where
- Rennes, FranceSee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 28 Feb 2023
- Expected to end
- 28 Feb 2039
- Type of study
- Interventional
- Treatments tested
- Standard care
- Record updated
- 17 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men newly diagnosed with prostate cancer who are treated at the university hospital of Guadeloupe or Rennes and live in the listed areas.
- Age
- 18 years and older
- Sex
- Men only
- Disease stage
- Newly diagnosed (incident) prostate cancer
Main reasons for not taking part
- Physical or mental health that the investigator judges to prevent taking part
- Protected adults (under guardianship, curatorship or safeguard of justice)
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adult patients with incident case of prostate cancer Patient consulting the University Hospital of Guadeloupe or the University Hospital of Rennes Patient who resides in the departments of Guadeloupe or Martinique or the community of Saint-Martin or in Britany Patient affiliated or beneficiary of the social security signed consent
Who cannot take part
- Physical or mental health judjed by the investigator as precluding participation in the research Protected adults (guardianship, curatorship, safeguard of justice)
Where in France
Also in 1 other country, 1 site
- CHU of RennesRennes, FranceContact: Valérie Hamony SoterNot yet recruiting
About the trial
What the trial wants to find out
The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .
The group in the trial
- Patients prostate cancerOther group
Patient with a confirmed diagnosis of prostate cancer will be included before starting any treatment. Recruitment will be carried out by urologists from the urology departments of the CHU of Guadeloupe and the CHU of Rennes.
Treatment: Standard care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.
- Plain-language title
- Studies what drives prostate cancer growth and spread over timeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 November 2025